ArticlePharmaceutical research2012
Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma.
Article in Pharmaceutical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 85 citations in OpenAlex.
- Preparation, characterization, and antioxidant activity of gallic acid grafted purple sweet potato polysaccharide.RSC advances · 2025Article
- Free Radical-Mediated Grafting of Natural Polysaccharides Such as Chitosan, Starch, Inulin, and Pectin with Some Polyphenols: Synthesis, Structural Characterization, Bioactivities, and Applications-A Review.Foods (Basel, Switzerland) · 2023Review
- Antioxidant Activity of Fucoidan Modified with Gallic Acid Using the Redox Method.Marine drugs · 2022Article
- Catechin-Albumin Conjugates: Enhanced Antioxidant Capacity and Anticancer Effects.International journal of food science · 2022Article
- Dextran-Curcumin Nanoparticles as a Methotrexate Delivery Vehicle: A Step Forward in Breast Cancer Combination Therapy.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Gallic Acid-Dextran Conjugate: Green Synthesis of a Novel Antioxidant Molecule.Antioxidants (Basel, Switzerland) · 2019Article
- Injectable Hydrogels for Cancer Therapy over the Last Decade.Pharmaceutics · 2019Review
- Synergistic Hypoglycemic Effects of Pumpkin Polysaccharides and Puerarin on Type II Diabetes Mellitus Mice.Molecules (Basel, Switzerland) · 2019Article
- Synthesis of Dextran-Phenoxodiol and Evaluation of Its Physical Stability and Biological Activity.Frontiers in bioengineering and biotechnology · 2019Article
- Anti-Cancerous Potential of Polyphenol-Loaded Polymeric Nanotherapeutics.Molecules (Basel, Switzerland) · 2018Review
- Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation.Drug delivery · 2017Article
- Polyphenols delivery by polymeric materials: challenges in cancer treatment.Drug delivery · 2017Review
- Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells.Scientific reports · 2017Article
- Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth.Oncotarget · 2016Article
- Graphene oxide - gelatin nanohybrids as functional tools for enhanced Carboplatin activity in neuroblastoma cells.Pharmaceutical research · 2015Article
- Two interconvertible folds modulate the activity of a DNA aptamer against transferrin receptor.Molecular therapy. Nucleic acids · 2014Article
- Synthesis, characterization and antimicrobial activity of conjugates based on fluoroquinolon-type antibiotics and gelatin.Journal of materials science. Materials in medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA polysaccharide-flavonoid conjugate was developend and proposed for the treatment of pancreatic ductal adenocarcinoma (PDAC).
methodsThe conjugate was synthesized by free radical grafting reaction between catechin and dextran. The chemical characterization of the conjugate was obtained by UV-Vis, 1H-NMR, FT-IR and GPC analyses, while the functionalization degree was determined by the Folin-Ciocalteu assay. The biological activity of the catechin-dextran conjugate was tested on two different cell lines derived from human pancreatic cancer (MIA PaCa-2 and PL45 cells), and the toxicity towards human pancreatic nestin-expressing cells evaluated.
resultsBoth the cancer cell lines are killed when exposed to the conjugate, and undergo apoptosis after the incubation with catechin-dextran which resulted more effective in killing pancreatic tumor cells compared to the catechin alone. Moreover, our experimental data indicate that the conjugate was less cytotoxic to human pancreatic nestin-expressing cells which are considered a good model of non-neoplastic pancreatic cells.
conclusionThe suitability of newly synthesized Dextran-Catechin conjugate in the treatment of PDAC was proved confirming the high potential application of the proposed macromolecula system in the cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.